When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MGNX - MacroGenics down 3% on uncertainty of margetuximab survival benefit
MacroGenics Inc.
MacroGenics (MGNX-2.9%) is down on double normal volume in response to results from a second interim survival analysis of Phase 3 clinical trial, SOPHIA, comparing lead drug margetuximab + chemo to Roche's Herceptin (trastuzumab) + chemo in patients with HER2-positive metastatic breast cancer who have previously received anti-HER2-targeted therapies. The data were presented at the San Antonio Breast Cancer Symposium.
More news on: MacroGenics, Inc., Healthcare stocks news, Stocks on the move,